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Introduction: Myeloma following kidney transplantation is a rare entity. It can be divided into two groups: relapse
of a previous myeloma and de novo myeloma. Some of these myelomas can be complicated by a monoclonal
immunoglobulin deposition disease, which is even less common. Less than ten cases of monoclonal
immunoglobulin deposition disease after renal graft have been reported in the literature. The treatment of these
patients is not well codified.
Case presentation: We report the case of a 43-year-old white European man who received a renal transplant for a
nephropathy of unknown etiology and developed a nephrotic syndrome with kidney failure at 2-years follow-up. We
diagnosed a de novo monoclonal immunoglobulin deposition disease associated with a kappa light chain multiple
myeloma, which is a very uncommon presentation for this disease. Three risk factors were identified in this patient:
Epstein–Barr virus reactivation with cytomegalovirus co-infection; intensified immunosuppressive therapy during two
previous rejection episodes; and human leukocyte antigen-B mismatches. Chemotherapy treatment and decrease in
the immunosuppressive therapy were followed by remission and slight improvement of renal function. A relapse
occurred 8 months later and his renal function worsened rapidly requiring hemodialysis. He died from septic shock 4
years after the diagnosis of monoclonal immunoglobulin deposition disease.
Conclusions: This rare case of post-transplant lymphoproliferative disorder with an uncommon presentation illustrates
the fact that treatment in such a situation is very difficult to manage because of a small number of patients reported
and a lack of information on this disease. There are no guidelines, especially concerning the immunosuppressive
therapy management.
Keywords: Light chain deposition disease (LCDD), Myeloma, Nephrotic syndrome, Post-transplant lymphoproliferative
disorder (PTLD), Renal graftIntroduction
Myeloma following kidney transplantation is a rare entity.
Approximately 30 cases have been described in the litera-
ture. The disease either occurs in the rare situation of re-
current myeloma – initial degradation of native renal
function caused by a myeloma followed by complete re-
mission allowing kidney transplantation – or in a context
of a post-transplant lymphoproliferative disorder (PTLD)
[1], that is, de novo myeloma. Renal monoclonal immuno-
globulins deposits can complicate the hematological* Correspondence: benjamin.savenkoff@orange.fr
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light chain amyloidosis, non-amyloid fibrillary glomerulo-
nephritis, immunotactoid glomerulonephritis and so on),
all of them resulting in renal function impairment. One of
these renal monoclonal immunoglobulins deposits patholo-
gies is called monoclonal immunoglobulin deposition dis-
ease (MIDD), also known as Randall disease [2]. De novo
MIDD is very exceptional in kidney transplant recipients,
less than ten cases have been reported in the literature
[3-6]. We present the case of a patient who underwent kid-
ney transplantation for nephropathy of unknown etiology,
then developed de novo MIDD associated with kappa light
chain multiple myeloma, revealed by a nephrotic syndrome
and kidney failure.ral Ltd. This is an Open Access article distributed under the terms of the Creative
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A 43-year-old white European man was referred to our
unit with an early end-stage renal failure disclosed by as-
thenia and malignant hypertension. At admission, labora-
tory tests showed: serum creatinine 7.0mg/dL; blood urea
nitrogen 200mg/dL; proteinuria 1.5g/24 hours (albumin-
uria 75%); negativity of Bence-Jones proteinuria; micro-
scopic hematuria; normal immunology tests; normal
serum protein electrophoresis (absence of monoclonal
gammopathy and no hypogammaglobulinemia). His renal
arteries were normal at the Doppler ultrasound. We tried
to perform a renal biopsy but we failed because we only
got fat tissue. He required peritoneal dialysis.
Eleven months later, a cadaveric renal graft was trans-
planted (pediatric donor who died from hemorrhagic stroke;
cytomegalovirus (CMV), status: donor+/recipient+). Ep-
stein–Barr virus (EBV), herpes simplex virus, and toxo-
plasmosis serologies were positive; other serologies were
negative. The human leukocyte antigen (HLA) compatibil-
ity was: A2-A29/B45-B51/DR1-DR14/DQ5-DQ5 (patient);
A2-A24/B7-B60/DR13-DR15/DQ5-DQ6 (donor). A
serum protein electrophoresis was performed in the pa-
tient at this time and was normal (absence of monoclonal
gammopathy and no hypogammaglobulinemia).
The initial immunosuppressive treatment included antil-
ymphocyte serum. The post-transplantation period was
uneventful with diuresis on day 1 and serum creatinine
1.7mg/dL (Modification of Diet in Renal Disease, MDRD,
formula: 48mL/minute/m2) at discharge. The immuno-
suppressive treatment at discharge was: prednisone (20mg
daily); ciclosporin (175mg twice a day); mycophenolate
(1000mg twice a day).
Two months after transplantation, CMV reactivation re-
quired oral treatment with valganciclovir and a decrease
in the immunosuppressive doses: prednisone (5mg daily);
ciclosporin 110mg twice a day; mycophenolate (1000mg
twice a day).
Seven months after transplantation, he was hospitalized
for renal function decline. A graft biopsy was performed
and showed borderline acute rejection; immunofluores-
cence for light and heavy immunoglobulin chains was
negative. Treatment with methylprednisolone (five intra-
venous boluses at decreasing doses) was followed by a de-
crease in serum creatinine which returned to its initial
level (1.3mg/dL).
He was hospitalized for the same reasons 18 months
after transplantation. The graft biopsy again showed bor-
derline acute rejection; immunofluorescence for light and
heavy immunoglobulin chains was again negative. Treat-
ment was again methylprednisolone (five intravenous bo-
luses at decreasing doses), with the same results.
His general status declined 22 months after transplant-
ation. At admission, an examination revealed rapid weight
loss, long-standing productive cough, and herpes zosterwith a Ramsay Hunt syndrome. His renal function was al-
tered: serum creatinine 2.4mg/dL (MDRD 31mL/minute/
1.73m2); proteinuria 7g/24 hours (6g albumin). The three
main hypotheses explaining this de novo nephrotic syn-
drome in this kidney transplant recipient were, by re-
ported frequency [7,8]: allograft glomerulopathy; recurrent
baseline nephropathy; and de novo glomerulopathy.
The immunosuppressive treatment was diminished be-
cause of a herpes zoster flare-up (prednisone 5mg twice
a day, ciclosporin 100mg twice a day, mycophenolate
500mg twice a day). He also received oral valaciclovir.
A new graft biopsy was performed and revealed severe
glomerular involvement with flocculocapsular synechiae,
scleronodular mesangial thickenings involving 13 of 30
glomeruli analyzed, a few zones of segmental and focal
hyalinosis, peritubular thickening and interstitial fibrosis
with tubular atrophy estimated at 50%. The tubules were
free of myelomatous casts. Immunofluorescence disclosed
monotypic kappa light chain immunoglobulin deposits in
the glomerular mesangium and peritubular spaces. Congo
red staining was negative. However, electron microscopic
examination was not performed because we did not ex-
pect to find monoclonal immunoglobulin deposits and
thus we fixated no specific sample in glutaraldehyde. Con-
sidering this biopsy, the diagnosis of MIDD was retained
[2]. Serum protein electrophoresis revealed a monoclonal
gammopathy with a kappa light chain monoclonal peak at
964mg/L (free light chains assay Freelite® produced by
Binding Site®), kappa/lambda ratio at 102, hypogammaglo-
bulinemia, and hypoalbuminemia at 25g/L related to the
nephrotic syndrome. A bone marrow aspiration showed
16% atypical plasma cells (high nucleus to cytoplasm ratio,
mature chromatin, nuclear inclusions) corresponding to a
kappa monotypic clonal population. These results con-
firmed the diagnosis of MIDD secondary to kappa light
chain multiple myeloma without extrarenal event. Polymer-
ase chain reaction on total blood samples was positive for
EBV at the time of diagnosis, signaling systemic EBV reacti-
vation. However no direct EBV research was performed
on the bone marrow examination at this moment. We
considered that both myeloma and MIDD occurred de
novo in this patient because there was no evidence of
plasma cell dyscrasia before, and the two previous graft bi-
opsies showed no immunoglobulin deposits.
He was transferred to the hematology unit and
treated for this PTLD by chemotherapy (bortezomib plus
dexamethasone). For the immunosuppressive treatment,
mycophenolate was discontinued progressively and ciclos-
porin was pursued, as was prednisone on days without
dexamethasone.
The treatment was followed by remission of his mye-
loma with a decrease in the serum light chains and a slight
improvement in renal function; serum creatinine im-
proved from 3.5 to 2.7mg/dL.
Figure 2 Standard stain, higher magnification than in Figure 1:
nodular glomerulosclerosis and presence of a protein cylinder
in one tube (related to the severe nephrotic syndrome).
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months after transplantation. A second chemotherapy
regimen was given (bortezomib-cyclophosphamide-dexa-
methasone) with decreased immunosuppression (ciclos-
porin reduced to 75mg twice a day).
Nevertheless his renal function worsened rapidly and he
required hemodialysis 3 years after transplantation. He re-
ceived a third line of chemotherapy (lenalidomid plus
dexamethasone) for a second relapse of his myeloma 54
months after transplantation.
It is important to notice that we performed a follow-up
bone marrow aspiration at this period that confirmed the
myeloma relapse and showed 10% of tumoral monoclonal
plasmocytes. The in situ hybridization did not permit us
to find EBV in these tumoral cells.
He finally died from septic shock in a context of post-
chemotherapy medullary aplasia at the age of 50, 4 years
after myeloma diagnosis and approximately 6 years after
transplantation (Figures 1, 2, 3, 4 and 5).
Discussion
Post-transplant myeloma is a rare disease and can occur
in the situation of recurrent myeloma (diagnosed or not
prior to transplantation) or can occur de novo. Several
problems are emphasized by this case report.
First of all, it can be difficult to assert the de novo char-
acter of myeloma because sometimes a kidney biopsy was
not performed or was not contributive before transplant-
ation. Moreover, as shown by Balamuthusamy et al. in
their case report [6] it can be a latent pre-transplant form
of myeloma or even a simple monoclonal gammopathy of
undetermined significance that may transform into an ag-
gressive myeloma after transplantation in the context of
immunosuppressive therapy. In our case we consideredFigure 1 Standard stain, low magnification: interstitial fibrosis
with tubular atrophy and presence of a sclerous glomerulus
with flocculocapsular synechiae.that both myeloma and MIDD occurred de novo after
the renal transplantation because we had strong argu-
ments to assert that there was no plasma cell dyscrasia
and no evidence of monoclonal immunoglobulin in the
patient’s blood or urine when he was referred to our
unit for the first time. In addition, two graft biopsies
were performed when his renal graft function worsened
and there was no evidence of monoclonal immuno-
globulin deposits. As shown by Taneda et al. in their
article [5] there is a gradual progression of kappa light
chain deposition in the renal allograft and these de-
posits are usually present within the kidney a long time
before it becomes clinically symptomatic.Figure 3 Standard stain, same magnification as in Figure 2:
major baseline membrane thickening.
Figure 4 Immunofluorescence with kappa light chains:
monotypic kappa light chain deposits in the glomeruli and in
the tubular baseline membranes.
Savenkoff et al. Journal of Medical Case Reports 2014, 8:205 Page 4 of 6
http://www.jmedicalcasereports.com/content/8/1/205The de novo form of myeloma is a B-cell PTLD, like dif-
fuse large B-cell lymphoma [1]. The incidence is low, ac-
counting for 3 to 13% of all PTLDs depending on the
series [9,10]. Patients are older compared to the lymph-
oma group [9]. Risk factors are still not clear but they
seem to be the same as for all PTLDs:
– primary EBV infection or EBV reactivation (with
CMV and hepatitis C virus co-infections identified
as risk cofactors) [9,11];
– major immunosuppressive treatment; in particular,
inductive antilymphocyte serum and long-term
anti-calcineurin drugs whereas other immunosup-
pressive agents are less associated with this risk orFigure 5 Immunofluorescence with lambda light chains:
absence of deposits (negative control).even have a protective effect as observed in certain
studies with antimetabolites and anti-mammalian
target of rapamycin drugs such as sirolimus) [9,12,13];
– HLA incompatibility, especially for HLA-B (direct
effect by creation of a latent antigen conflict with
secretion of lymphoproliferative cytokines and indirect
effect by causing graft rejection requiring more
intense immunosuppression) [14-16].
Our patient presented all the above risk factors: EBV
reactivation with CMV co-infection; intensified immuno-
suppressive therapy during both rejection episodes; HLA
mismatches, particularly for HLA-B.
These risk factors should be systematically searched
among patients with de novo plasma cell dyscrasia, which
is rarely emphasized in the literature.
Regarding the management strategy for these patients, a
systematic screening for EBV in tumor plasma cells using
an in situ hybridization technique would be advisable be-
cause the majority of these hematological diseases are
virus related [17]. If viral reactivation is documented, an
antiviral treatment can be proposed; in particular, ganci-
clovir because Foscavir® (foscarnet) is nephrotoxic [18,19].
In our case, direct EBV tests were not performed at the
time of diagnosis and no antiviral treatment was given.
A third problem concerning de novo myeloma or MIDD
after transplantation is that the treatment strategy is not
well codified.
It would be probably advisable to diminish the immuno-
suppressive treatment because several studies have demon-
strated that PTLDs regress after decreasing anti-rejection
treatments [12]. No clear guidelines are available, but it
would appear reasonable to reduce the anti-calcineurin
dose first because several studies have linked these agents
with a higher relative risk of PTLD compared with other
treatments [9,13,20]. In our patient, the mycophenolate
dose was reduced first and ciclosporin was maintained at
the same dose, which illustrates the heterogeneous manage-
ment strategy, especially concerning the immunosuppres-
sive treatment. This immunosuppressive treatment
strategy is not well clarified in the literature dealing
with de novo plasma cell dyscrasias. Usually, immuno-
suppressive therapy is rapidly stopped when graft func-
tion worsens because of a very high infection risk
compared to the benefit of the treatment.
New therapeutic options are being studied for unrespon-
sive forms of the disease, for example plasma exchange [4],
immunotherapy [21] or injection of anti-EBV cytotoxic
lymphocytes [22].
Conclusions
Currently, the development of myeloma in a kidney trans-
plant recipient raises several problems related to the lack
of specific therapeutic guidelines, the rapid decline of renal
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to reduced immunosuppressive treatment, chemotherapy-
related nephrotoxicity), and the major risk of infection
(immunosuppression, myeloma-related hypogammaglobu-
linemia, vascular access for dialysis).
In this case report we outline and discuss all of the
above problems. First of all, the disease occurred as a de
novo glomerulopathy with renal graft failure and nephrotic
syndrome. We tried to gather strong arguments to assert
the de novo character of MIDD and myeloma which is not
always easy. Then, our patient presented the three main
risk factors for PTLD which are rarely mentioned in the
literature. This raises also the question of EBV reactivation
treatment. We illustrated the fact that management strat-
egy is not homogeneous and that clinicians, nephrologists
or hematologists, have to face many problems when treat-
ing these patients. Last but not least, this case report em-
phasizes the very bad prognosis of this kind of PTLD that
often leads to end-stage renal graft failure and severe in-
fectious complications.
To conclude, a systematic report study of de novo mye-
lomas or plasma cell dyscrasias among kidney transplant
recipients would be useful to better define the characteris-
tic features of these patients and to organize large-scale
trials to determine a more evidence-based management
strategy.
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